At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 162 enrolled
Drug / intervention
Abemaciclibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma
In Brief
A Phase 2 clinical trial evaluating Abemaciclib for Breast Cancer and 3 related conditions. Completed, enrolled 162 participants across 44 sites in 9 countries.
Detailed Summary
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as abemaciclib in participants with hormone receptor positive breast cancer, non-small cell lung cancer (NSCLC), or melanoma that has spread to the brain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Non-small Cell Lung Cancer, Melanoma, Brain Metastases
CountriesAustralia, Austria, Belgium, Canada, France, Israel, Italy, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2014
Enrollment StartApr 2015
Primary CompletionNov 2018
Study CompletionNov 2019
TodayJul 2026
First PostedDec 4, 2014
Enrollment StartApr 20, 2015
Primary CompletionNov 8, 2018
Study CompletionNov 8, 2019
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 11.6 years ago
Interventions
Abemaciclibdrug
Administered orally